Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glenmark Begins Phase III Trial of Anti-Viral Combo in COVID-19 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Glenmark Begins Phase III Trial of Anti-Viral Combo in COVID-19

To test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment.

By: Contract Pharma

Contract Pharma Staff

Glenmark Pharmaceuticals, a global pharmaceutical company, began a new randomized, open-label study in 158 hospitalized patients to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment.

Favipiravir is an oral antiviral drug, approved in Japan since 2014, that inhibits viral replication. Umifenovir is another oral antiviral drug licensed for treatment and prophylaxis of influenza A and B infections in Russia and China. Umifenovir impedes the viral attachment to cells and acts as a viral entry inhibitor. Additionally it exhibits modulatory effects on the immune system and induces interferon-production. The combined use of Favipiravir and Umifenovir acting on different mechanisms offers a comprehensive antiviral cover on pre-entry and post-entry life-cycle of the SARS-CoV-2 virus. Both antivirals inhibited virus infection in vitro and have shown efficacy in COVID-19 clinical trials.

Glenmark is also conducting Phase III trials of Favipiravir as a COVID-19 monotherapy option in 150 patients, enrolled from nine government and private hospitals across India.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics